A phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors - ST101-101 Phase 1-2 Study in Advanced Cancer

开始日期2020-07-13

申办/合作机构

Sapience Therapeutics, Inc.

NCT04478279

/ Active, not recruiting临床1/2期

A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors

This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.

开始日期2020-07-01

申办/合作机构

Sapience Therapeutics, Inc.

100 项与 Lucicebtide 相关的临床结果

登录后查看更多信息

100 项与 Lucicebtide 相关的转化医学

登录后查看更多信息

100 项与 Lucicebtide 相关的专利（医药）

登录后查看更多信息

项与 Lucicebtide 相关的文献（医药）

Frontiers in Immunology

The C/EBPβ antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses

Article

作者: Koester, Mark ; Ramirez, Rick ; Merutka, Gene ; Diehl, Julia ; Vainstein-Haras, Abi ; Leong, Siok F ; Abbate, Franco ; Mendelson, Karen ; Gallagher, Erin ; Mattes, Zachary F ; Scuoppo, Claudio ; Kappel, Barry J ; Ghamsari, Lila ; Rotolo, Jim A

Immune-checkpoint inhibitors (ICIs) have shown unprecedented success in a subset of immunogenic tumors, however a host of patients with advanced solid tumors fail to respond well or at all to immunotherapy. Refractory tumors commonly display a tumor microenvironment (TME) rich in immunosuppressive macrophages (M2-like) that suppress adaptive immunity and promote tumor progression. The ability to reprogram macrophages in the TME into an immune-active state holds great promise for enhancing responses to ICIs. Lucicebtide (previously referred to as ST101) is a peptide antagonist of the transcription factor C/EBPβ, a key activator of the transcriptional program in immunosuppressive macrophages. Here we show that lucicebtide exposure reprograms human immunosuppressive M2-like macrophages to a pro-inflammatory M1-like phenotype, restores cytotoxic T cell activation in immunosuppressed co-culture assays in vitro, and further increases T-cell activity in M1-like/T cell co-cultures. In immunocompetent, macrophage-rich triple-negative breast and colorectal cancer models, lucicebtide induces repolarization of tumor-associated macrophages (TAMs) to a pro-inflammatory M1-like phenotype and suppresses tumor growth. Lucicebtide synergizes with anti-PD-1 therapy and overcomes resistance to checkpoint inhibition in anti-PD-1-refractory tumors, but in vivo responses are impaired by systemic macrophage depletion, indicating that macrophage reprogramming is integral to lucicebtide activity. These results identify lucicebtide as a novel immunomodulator that reprograms immunosuppressive macrophage populations to enhance anti-tumor activity and suggests its utility for combination strategies in cancers with poor response to ICIs.

项与 Lucicebtide 相关的新闻（医药）

2025-06-08

·药明康德

缓解率较标准治疗翻倍的多肽组合疗法；每周两次长效多肽向EMA递交上市申请…… | TIDES周报

近期，全球多肽和寡核苷酸（TIDES）领域迎来系列进展。Zealand Pharma公司宣布向欧洲药品管理局（EMA）递交其多肽疗法glepaglutide的上市申请，用于治疗短肠综合征（SBS）成人患者。用于治疗真性红细胞增多症（PV）的多肽疗法rusfertide达3期临床试验终点，需放血治疗的患者比例显著降低。治疗胶质母细胞瘤（GBM）的C/EBPβ拮抗剂lucicebtide（ST101）获积极2期临床试验结果。Glepaglutide：向EMA提交上市申请Zealand Pharma公司宣布向EMA递交其长效胰高血糖素样肽-2（GLP-2）类似物glepaglutide的上市许可申请（MAA），用于治疗SBS成人患者。Glepaglutide是一种装于自动注射器中的液体产品，设计用于每周两次的皮下给药，旨在减少或消除SBS患者对肠外营养支持（PS）的需求。美国FDA已授予该疗法治疗SBS的孤儿药资格。该递交主要是基于随机双盲关键3期试验EASE-1的结果，并得到两项正在进行的长期扩展试验EASE-2和EASE-3的中期结果和机制试验EASE-4的结果支持。EASE-1研究中，与安慰剂相比，每周两次glepaglutide给药在第24周显著降低患者每周PS所需总液体体积（P=0.0039）。第24周时，每周两次接受glepaglutide治疗患者的PS液体体积较基线平均降低5.13公升/周。安慰剂治疗仅导致所需PS液体体积降低2.85公升/周。对于接受每周两次glepaglutide治疗的患者，14%的患者（n=5）实现不再需要PS辅助治疗，而安慰剂治疗患者均不能停用PS。Rusfertide：公布3期临床试验的新数据Protagonist Therapeutics公司与武田（Takeda）公布了3期研究VERIFY的积极新结果。该试验主要评估每周一次的rusfertide自我给药皮下注射，在那些标准治疗下仍血容量控制不佳且依赖放血疗法的真性红细胞增多症患者中的疗效与安全性。Rusfertide是一种潜在“first-in-class”的在研天然激素铁调素的多肽模拟物，已获得美国FDA的孤儿药资格和快速通道资格。此次公布的分析结果显示，该研究达到了其主要终点，rusfertide联合当前标准治疗在高危和低危PV患者中使临床缓解率较安慰剂联合当前标准治疗组患者翻倍（76.9%对比32.9%），显著降低需放血治疗的患者比例。所有关键次要终点也均达到统计学显著差异，包括rusfertide联合治疗组需放血治疗的患者比例显著下降（27%对比78%），保持血细胞比容水平低于45%的患者比例显著提升（62.6%对比14.4%），患者报告的结局也有所改善。此外，未报告任何与rusfertide相关的严重不良事件。EO4010：公布1/2期联合治疗试验数据Enterome公司公布了其在研免疫疗法EO4010的1/2期临床试验AUDREY的积极数据。该研究旨在评估EO4010联合纳武利尤单抗（nivolumab）±贝伐珠单抗（bevacizumab）治疗微卫星稳定（MSS）/错配修复功能正常（pMMR）转移性结直肠癌（mCRC）的效果。EO4010是一种由五种微生物衍生肽组成的疫苗，这些肽模拟了五种常见于结直肠癌患者的肿瘤相关抗原（TAA）——BIRC5、FOXM1、UBE2C、CDC20和KIF2C，旨在激活患者的肿瘤特异性CD8阳性T细胞，引导其识别并杀死表达这些抗原的癌细胞。此次公布的结果显示，EO4010显示出良好的安全性和耐受性。中位随访时间为15.4个月时，20名MSS/pMMR mCRC患者的12个月生存率为40%，中位生存时间为11.3个月。目前，患者的生存曲线已趋于平稳，34%（7/20）的患者仍存活。此外，80%接受EO4010联合纳武利尤单抗治疗的患者体内检测到针对肿瘤相关抗原的特异性免疫反应。这些积极结果支持进一步开发EO4010治疗结直肠癌的潜力。Lucicebtide：公布2期临床试验结果Sapience Therapeutics公司公布了其潜在“first-in-class”的C/EBPβ拮抗剂lucicebtide治疗胶质母细胞瘤的2期临床试验数据。Lucicebtide已获得美国FDA授予用于治疗复发性GBM的快速通道资格，以及美国FDA和欧盟委员会授予的孤儿药资格，用以治疗神经胶质瘤。此次公布的结果显示，lucicebtide作为单一疗法和与标准护理（SoC）联合使用具有良好的耐受性。截至2025年5月6日的数据，新确诊的GBM队列中，9名患者中有5名尚未出现疾病进展（10-24+个月），6名患者在数据截止时仍然存活；复发性GBM队列中，9名患者中有4名获得疾病控制，其中2名为部分缓解（PR），3名患者在数据截止时仍然存活。[212Pb]VMT-α-NET：公布1/2a期临床试验的中期数据Perspective Therapeutics公司公布了其候选多肽偶联核素疗法[212Pb]VMT-α-NET的1/2a期临床试验的最新中期数据。该研究旨在评估[212Pb]VMT-α-NET在表达SSTR2的不可切除/转移性神经内分泌瘤（NET）患者中的疗效和安全性，这些患者既往未接受过放射性药物治疗（RPT），并且放射学证据显示其肿瘤在入组前12个月内已发生疾病进展。截至2025年4月30日的数据，该疗法安全性良好，在接受至少一种治疗的总共42名患者中，没有观察到剂量限制性毒性，也没有因不良事件而停药。在队列2的7名患者中，有4名达到了研究者评估的客观缓解，其中3名缓解已确认并持续维持，1名需进一步确认；而在队列1和2的共计9名患者中，有7名在超过一年的随访期内保持无疾病进展。ARO-ALK7：启动1/2a期临床试验Arrowhead Pharmaceuticals公司宣布，其用于治疗肥胖的在研小干扰RNA（siRNA）疗法ARO-ALK7的1/2a期临床试验已为第一批受试者给药。ARO-ALK7旨在沉默脂肪细胞中ACVR1C基因的表达，以减少激活素受体样激酶7（ALK7）的产生，ALK7在调节脂肪组织能量稳态的通路中充当受体。在临床前研究中，ARO-ALK7抑制了脂肪组织中ALK7的表达，从而能在保留瘦肌肉的同时减少体重和脂肪质量。新闻稿指出，ARO-ALK7是首个进入临床研究、靶向脂肪组织中表达基因的RNA干扰（RNAi）治疗药物。SC-102：IND申请获得FDA许可星联肽生物宣布，其EphA2靶向多肽偶联药物（PDC）SC-102的IND申请获得了美国FDA许可，可开展临床试验评估SC-102治疗表达EphA2的晚期或转移性实体瘤患者的安全性和有效性。SC-102通过特异性结合表达EphA2的肿瘤细胞，释放毒性载荷，从而抑制肿瘤生长。EphA2在多种肿瘤细胞表面高表达，SC-102有望治疗包括卵巢癌、乳腺癌、胰腺癌在内的多种实体瘤。此前，SC-102已在中国获批开展临床试验，目前正处于剂量递增研究阶段。已有临床数据显示，SC-102初步展现出良好的疗效和安全性。参考资料：[1] Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity. Retrieved June 5, 2025, from https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-initiates-phase-12a-study-aro-alk7[2] Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting. Retrieved June 5, 2025, from https://www.globenewswire.com/news-release/2025/05/30/3091346/0/en/Perspective-Therapeutics-Highlights-Updated-Interim-Data-from-its-Ongoing-Phase-1-2a-Clinical-Trial-of-212Pb-VMT-%CE%B1-NET-at-the-2025-ASCO-Annual-Meeting.html[3] Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome. Retrieved June 5, 2025, from https://www.globenewswire.com/news-release/2025/06/02/3091534/0/en/Zealand-Pharma-submits-Marketing-Authorization-Application-to-the-European-Medicines-Agency-for-glepaglutide-in-short-bowel-syndrome.html[4] Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera. Retrieved June 5, 2025, from https://www.takeda.com/newsroom/newsreleases/2025/polycythemia-vera-rusfertide-study/[5] Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Retrieved June 5, 2025, from https://www.prnewswire.com/news-releases/sapience-therapeutics-provides-data-update-from-phase-2-trial-of-lucicebtide-in-patients-with-glioblastoma-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting-302470177.html[6] Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025. Retrieved June 5, 2025, from https://www.globenewswire.com/news-release/2025/05/30/3090836/0/en/Enterome-presents-positive-Phase-1-2-MSS-pMMR-metastatic-colorectal-cancer-data-in-patients-treated-with-EO4010-OncoMimics-immunotherapy-plus-nivolumab-at-ASCO-2025.html[7] 星联肽EphA2靶向PDC药物SC-102获批美国临床. Retrieved June 5, 2025, from https://mp.weixin.qq.com/s/Z_VtQBFnZHfLUAs8ZmSNJw免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

孤儿药临床3期临床结果寡核苷酸快速通道

2025-06-03

·PipelineReview

Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

-Clinical benefit and favorable safety profile as monotherapy and in combination with SOC- -Biomarker data supports MOA: decreased GBM mesenchymal signature and increased TME immune activity- TARRYTOWN, NY, USA I June 2, 2025 I Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced updated positive clinical and biomarker data from its Phase 2 clinical trial of lucicebtide (formerly known as ST101), a first-in-class antagonist of C/EBPβ, in patients with glioblastoma (GBM). The data were featured during an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025, in Chicago and online. “GBM represents a devastating disease carrying a poor prognosis and high mortality rate, and there is a significant need for new, efficacious treatment options,” said Fabio Iwamoto, MD, Division of Neuro-Oncology, New York-Presbyterian/Columbia University Irving Medical Center. “The growing body of data from this Phase 2 study, which demonstrate a marked progression free and overall survival benefit, continue to support that lucicebtide could serve as a well-tolerated, meaningful addition to the GBM treatment paradigm. I look forward to deepening our understanding of the potential for lucicebtide to improve outcomes and offer hope to patients for whom limited alternatives exist.” Sapience Chief Medical Officer, Dr. Abi Vainstein-Haras, added, “These updated results reinforce lucicebtide’s compelling clinical and safety profile, and support its potential to serve as a standalone therapy or in combination with existing treatments. The opportunity to collect biopsies in this patient population gave us a unique opportunity for biomarker analysis to demonstrate the meaningful effects of lucicebtide.” Oral Presentation Highlights Include: A copy of the presentation is available under the Presentations section of the Sapience Therapeutics website . About Lucicebtide (formerly known as ST101) Lucicebtide, a first-in-class antagonist of C/EBPβ, has completed the main portion of a Phase 2 dose expansion study in recurrent glioblastoma (rGBM) ( NCT04478279 ). An ongoing Window-of-Opportunity sub-study is evaluating lucicebtide in combination with radiation and temozolomide in patients with newly diagnosed GBM (ndGBM) and as a monotherapy in patients with rGBM, with patients receiving lucicebtide before and after surgical resection in both cohorts. Lucicebtide has been granted Fast Track designation for rGBM from the U.S. Food and Drug Administration (U.S. FDA) and orphan designations for glioma from the U.S. FDA and the European Commission. About Sapience Therapeutics Sapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics to address oncogenic and immune dysregulation that drive cancer. With in-house discovery capabilities, Sapience has built a pipeline of therapeutic candidates called SPEARs™ (Stabilized Peptides Engineered Against Regulation) that disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. Sapience can also direct cargo to cell surface targets with their new class of molecule called SPARCs™ (Stabilized Peptides Against Receptors on Cancer), enabling delivery of radioisotope payloads such as α-particles to cancer cells. Sapience is advancing its lead programs, lucicebtide (formerly known as ST101), a first-in-class antagonist of C/EBPβ, and ST316, a first-in-class antagonist of β-catenin, through Phase 2 clinical trials. For more information on Sapience Therapeutics, please visit https://sapiencetherapeutics.com/ and engage with us on LinkedIn . SOURCE: Sapience Therapeutics

临床2期快速通道孤儿药ASCO会议临床结果

2025-06-02

·PRNewswire

Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

-Clinical benefit and favorable safety profile as monotherapy and in combination with SOC- -Biomarker data supports MOA: decreased GBM mesenchymal signature and increased TME immune activity- TARRYTOWN, N.Y., June 2, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced updated positive clinical and biomarker data from its Phase 2 clinical trial of lucicebtide (formerly known as ST101), a first-in-class antagonist of C/EBPβ, in patients with glioblastoma (GBM). The data were featured during an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025, in Chicago and online. "GBM represents a devastating disease carrying a poor prognosis and high mortality rate, and there is a significant need for new, efficacious treatment options," said Fabio Iwamoto, MD, Division of Neuro-Oncology, New York-Presbyterian/Columbia University Irving Medical Center. "The growing body of data from this Phase 2 study, which demonstrate a marked progression free and overall survival benefit, continue to support that lucicebtide could serve as a well-tolerated, meaningful addition to the GBM treatment paradigm. I look forward to deepening our understanding of the potential for lucicebtide to improve outcomes and offer hope to patients for whom limited alternatives exist." Sapience Chief Medical Officer, Dr. Abi Vainstein-Haras, added, "These updated results reinforce lucicebtide's compelling clinical and safety profile, and support its potential to serve as a standalone therapy or in combination with existing treatments. The opportunity to collect biopsies in this patient population gave us a unique opportunity for biomarker analysis to demonstrate the meaningful effects of lucicebtide." Oral Presentation Highlights Include: Lucicebtide was well-tolerated as a monotherapy and in combination with standard-of-care (SOC) agents. Lucicebtide combination with SOC Window-of-Opportunity study in newly diagnosed GBM cohort (n=9), data cut May 6, 2025: 5/9 patients yet to experience disease progression (10-24+ months) 6/9 patients are alive as of the data cutoff date (10-26+ months) Lucicebtide Window-of-Opportunity study in recurrent GBM cohort (n=9), data cut May 6, 2025: 4/9 patients had disease control, with two partial responses 3/9 patients remain alive as of data cutoff Window-of-Opportunity biomarker results demonstrate: Lucicebtide crossed the blood-brain barrier, demonstrated uptake into the tumor and target engagement Immune activation in the tumor microenvironment (TME) evidenced by increased macrophage M1/M2 ratio and CD8 T cell infiltration Meaningful reductions in mesenchymal gene signature in tumor cells as shown by spacial transcriptomics analysis Data support lucicebtide and C/EBPβ antagonism as a differentiated and promising therapeutic approach for patients with GBM. A copy of the presentation is available under the Presentations section of the Sapience Therapeutics website. About Lucicebtide (formerly known as ST101) Lucicebtide, a first-in-class antagonist of C/EBPβ, has completed the main portion of a Phase 2 dose expansion study in recurrent glioblastoma (rGBM) (NCT04478279). An ongoing Window-of-Opportunity sub-study is evaluating lucicebtide in combination with radiation and temozolomide in patients with newly diagnosed GBM (ndGBM) and as a monotherapy in patients with rGBM, with patients receiving lucicebtide before and after surgical resection in both cohorts. Lucicebtide has been granted Fast Track designation for rGBM from the U.S. Food and Drug Administration (U.S. FDA) and orphan designations for glioma from the U.S. FDA and the European Commission. About Sapience Therapeutics Sapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics to address oncogenic and immune dysregulation that drive cancer. With in-house discovery capabilities, Sapience has built a pipeline of therapeutic candidates called SPEARs™ (Stabilized Peptides Engineered Against Regulation) that disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. Sapience can also direct cargo to cell surface targets with their new class of molecule called SPARCs™ (Stabilized Peptides Against Receptors on Cancer), enabling delivery of radioisotope payloads such as α-particles to cancer cells. Sapience is advancing its lead programs, lucicebtide (formerly known as ST101), a first-in-class antagonist of C/EBPβ, and ST316, a first-in-class antagonist of β-catenin, through Phase 2 clinical trials. For more information on Sapience Therapeutics, please visit and engage with us on LinkedIn. SOURCE Sapience Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果快速通道孤儿药ASCO会议

100 项与 Lucicebtide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床2期	美国	Sapience Therapeutics, Inc.	2020-07-01
晚期恶性实体瘤	临床2期	英国	Sapience Therapeutics, Inc.	2020-07-01
多形性胶质母细胞瘤	临床2期	美国	Sapience Therapeutics, Inc.	2020-07-01
多形性胶质母细胞瘤	临床2期	英国	Sapience Therapeutics, Inc.	2020-07-01
复发性黑色素瘤	临床2期	美国	Sapience Therapeutics, Inc.	2020-07-01
复发性黑色素瘤	临床2期	英国	Sapience Therapeutics, Inc.	2020-07-01
转移性乳腺癌	临床2期	美国	Sapience Therapeutics, Inc.	2020-07-01
转移性乳腺癌	临床2期	英国	Sapience Therapeutics, Inc.	2020-07-01
转移性黑色素瘤	临床2期	美国	Sapience Therapeutics, Inc.	2020-07-01
转移性黑色素瘤	临床2期	英国	Sapience Therapeutics, Inc.	2020-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04478279 (WoO study, ASCO2025)	临床2期	胶质母细胞瘤 C/EBPβ	-	Lucicebtide 500mg QW	壓製簾壓範積膚蓋願觸(顧獵積鹹鬱積窪廠繭鹹) = 窪願夢鹹蓋簾淵網膚夢獵獵積鬱製顧獵蓋淵衊 (遞鏇憲窪願鏇廠餘鏇製 ) 更多	积极	2025-05-30
NCT04478279 (WoO study, ASCO2025)	临床2期	胶质母细胞瘤 C/EBPβ	-	lucicebtide (ST101) (Chemoradiation)	鹹鑰網築積壓鬱廠繭製(繭製餘鹽夢憲憲範糧膚) = 顧醖艱膚築選餘淵鬱範壓選製願淵淵鏇觸繭淵 (範艱淵簾繭獵壓築鬱積 )	积极	2025-05-30
NCT04478279 (ASCO2024) 人工标引	临床2期	复发性胶质母细胞瘤三线	36	ST101 (P2 cohort)	鏇夢願繭鬱積膚構積繭(憲蓋網齋壓壓鹽構鏇顧) = 鬱觸襯衊糧蓋選廠壓構觸網築窪積願觸膚窪獵 (衊膚製憲範衊選襯鏇鹹 ) 更多	积极	2024-05-24
NCT04478279 (ASCO2024) 人工标引	临床2期	复发性胶质母细胞瘤三线	36	ST101 (WoO cohort)	鏇夢願繭鬱積膚構積繭(憲蓋網齋壓壓鹽構鏇顧) = 淵糧網觸構糧齋窪簾製觸網築窪積願觸膚窪獵 (衊膚製憲範衊選襯鏇鹹 ) 更多	积极	2024-05-24
NCT04478279 (Corporate Publications) 人工标引	临床2期	胶质母细胞瘤新辅助 \| 辅助	12	ST101 (Newly diagnosed GBM)	鬱鹽製鑰遞餘壓窪襯膚(鑰廠齋觸簾齋顧選築醖) = 夢範鑰艱鑰壓壓夢憲蓋廠簾選夢願膚積網艱餘 (選窪餘觸鬱範醖齋夢廠 )	积极	2023-11-17
NCT04478279 (Corporate Publications) 人工标引	临床2期	胶质母细胞瘤新辅助 \| 辅助	12	ST101 (Recurrent GBM)	鬱鹽製鑰遞餘壓窪襯膚(鑰廠齋觸簾齋顧選築醖) = 製窪選鑰廠齋鑰獵願憲廠簾選夢願膚積網艱餘 (選窪餘觸鬱範醖齋夢廠 ) 更多	积极	2023-11-17
NCT04478279 (CTNI-44, SNO2023)	临床1/2期	多形性胶质母细胞瘤新辅助 C/EBPβ	12	ST101 500 mg IV	鏇襯淵廠襯夢觸鑰窪襯(襯觸顧襯築餘壓襯淵顧) = 願簾構顧衊顧蓋範網艱醖夢夢鑰膚艱夢衊積鏇 (選淵鹽選遞遞壓願簾糧, 53+)	积极	2023-11-10
CTNI-49 (SNO2022)	临床2期	复发性胶质母细胞瘤	14	ST101 500mg IV weekly	艱製淵範襯鑰鑰膚網餘(齋餘壓齋築糧蓋網淵窪) = minor infusion related reactions being the most common adverse event 鬱鑰獵餘艱築糧積膚網 (鏇鑰鏇鑰憲艱願齋築鬱 )	积极	2022-11-14
NCT04478279 (ASCO2022) 人工标引	临床1期	难治恶性实体肿瘤	25	ST101	壓淵醖淵蓋鹽構齋醖窪(齋鬱製鬱網築襯鹽鏇繭) = The only AEs of note were G1-2 histaminergic infusion-related reactions (IRRs), largely pruritis and urticaria 繭艱構蓋餘鑰膚淵鑰壓 (膚鬱鬱憲鹽餘襯衊壓醖 )	积极	2022-06-02
SABCS2022	临床1/2期	乳腺癌 C/EBPβ	-	ST101	淵製淵構願觸醖蓋壓簾(築齋構遞築簾餘蓋獵願) = 夢壓製膚範繭構構繭糧鬱窪壓廠鹹淵膚艱夢簾 (齋鬱夢鹽憲製構鹽鏇壓 )	-	2022-02-15
AACR2021	临床1/2期	乳腺癌	-	ST101	範鹹繭襯餘艱廠壓鬱鑰(積獵鹽選淵蓋構顧醖衊) = 鑰鹹壓網餘衊鏇廠鹹積憲願艱鹽餘壓壓艱觸艱 (窪壓窪繭憲網憲窪繭鏇 )	-	2021-07-01